An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed  by Sherman, Steven et al.
Clinical Therapeutics/Volume 37, Number 11, 2015
An Indirect Comparison of Everolimus Versus Axitinib in
US Patients With Advanced Renal Cell Carcinoma in
Whom Prior Sunitinib Therapy Failed
Steven Sherman, MPH1; Billy Amzal, MSc, MPA, PhD1; Emiliano Calvo, MD, PhD2;
Xufang Wang, MD, MBA3; Jinhee Park, PhD3; Zhimei Liu, PhD3; Chinjune Lin, MD3;
and Roman Casciano, MSc1
1LASER Analytica, New York, New York; 2Centro Integral Oncolo´gico Clara Campal and START Madrid,
Madrid, Spain; and 3Novartis Pharmaceuticals Corporation, East Hanover, New JerseyAccepted for publication September 27, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.09.013
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ABSTRACT
Purpose: The purpose of this study was to perform a
weight-adjusted indirect comparison to approximate
the relative efﬁcacy of everolimus versus axitinib
among patients with second-line metastatic renal cell
carcinoma in whom sunitinib therapy previously failed.
Methods: Individual patient data from the RECORD-
1 (Renal Cell Cancer Treatment With Oral RAD001
Given Daily) Phase III clinical trial provided information
for patients taking everolimus. Summary baseline clinical
and demographic characteristics and progression-free
survival (PFS) outcomes were available for patients taking
axitinib who were included in the AXIS (axitinib versus
sorafenib) Phase III clinical trial. A Bayesian latent class
mixture model differentiating responders and nonres-
ponders and with imbedded Weibull regression on PFS
was used to identify sex, Memorial Sloan-Kettering
Cancer Center risk score, and time receiving prior
sunitinib therapy as prognostic factors for PFS based on
posterior probability 495%. Patients taking everolimus
were weighted up or down based on their combination of
prognostic variables. Weights were calculated by dividing
the proportion of patients observed in AXIS for a given
characteristic by the proportion observed in RECORD-1
and taking the product of the values derived for all three
weighting variables considered. Weighted PFS distribu-
tions were derived with bootstrapped 95% CIs and
compared with those reported for the AXIS trial.
Findings: After weighting, distributions of the 3 key
baseline characteristics were more closely aligned
between the 2 studies; however, some differences
remained. A slightly lower rate of poor-risk patients
was evident in RECORD-1 (30%) versus AXIS
(36%), and a 9% lower proportion of males was
observed in the everolimus group compared with the2552axitinib group. Distributions of time receiving prior
sunitinib therapy were almost equivalent between the
treatment arms. A median PFS of 4.7 months (95%
CI, 3.5–10.6 months) was observed for patients in the
weighted everolimus group compared with 4.8
months (95% CI, 4.5–6.4 months) in the AXIS trial.
Implications: Similar median PFS point estimates
and overlapping CIs suggest that everolimus and
axitinib have similar efﬁcacy. Although these results
do not negate the need for direct comparison, this
study may be used to inform clinical and reimburse-
ment decisions until such evidence is available. (Clin
Ther. 2015;37:2552–2559) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
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Metastatic renal cell carcinoma (mRCC) is one of the
leading causes of cancer deaths in the United States1;
however, in recent years, several therapy options have
become available to treat advanced RCC or mRCC.
First-line treatments with National Comprehensive
Cancer Network category 1 recommendations include
sunitinib, temsirolimus, bevacizumab plus interferon
alfa, pazopanib, high-dose interleukin 2, and sorafe-
nib,2 although recent real-world evidence suggests thatVolume 37 Number 11
S. Sherman et al.sunitinib currently represents the dominant ﬁrst-line
treatment.3 Despite the observed progression-free
survival (PFS) beneﬁt from ﬁrst-line sunitinib therapy,
most patients require a second-line treatment within 1
year.4 After failure of ﬁrst-line sunitinib therapy,
according to National Comprehensive Cancer Net-
work guidelines, everolimus and axitinib are the only
agents that currently have category 1 evidence for
second-line treatment of mRCC.2
Everolimus, a mammalian target of rapamycin path-
way inhibitor, was approved by the US Food and Drug
Administration in 2009 as a second-line treatment for
advanced RCC after failure of the vascular endothelial
growth factor tyrosine kinase inhibitor sunitinib and
sorafenib.5 In the pivotal Phase III RECORD-1 (Renal
Cell Cancer Treatment With Oral RAD001 Given
Daily) clinical trial, patients with mRCC in whom
ﬁrst-line sunitinib and/or sorafenib therapies previously
failed were assigned to treatment with either everolimus
or placebo plus best supportive care. The PFS and safety
proﬁles were assessed for each treatment group until
progression, death, or discontinuation, whichever came
ﬁrst. The study resulted in a signiﬁcant PFS improve-
ment of 67% (hazard ratio [HR] ¼ 0.33; 95% CI,
0.25-0.43, P o 0.001) for patients treated with ever-
olimus versus placebo.6 A similar trend was observed in
those with sunitinib as their only prior targeted therapy,
with a median PFS of 4.6 versus 1.8 months (HR ¼
0.22; 95% CI, 0.09–0.55) for patients treated with
everolimus and best supportive care, respectively.7
Axitinib is a vascular epidermal growth factor
receptor 1 to 3, c-KIT, and platelet-derived growth
factor receptor inhibitor approved in 2012 to treat
advanced RCC after failure of prior systemic therapy.8
The AXIS (axitinib vs sorafenib) Phase III clinical trial
examined the PFS and safety proﬁles among patients
who had progressed with a ﬁrst-line regimen of
sunitinib, bevacizumab plus interferon alfa, temsiroli-
mus, or cytokine therapy. Patients were randomized to
receive either axitinib or sorafenib treatment. Overall,
patients had signiﬁcant improvement with axitinib
compared with sorafenib, with a median PFS of 6.7
months for patients receiving axitinib versus 4.7
months for patients receiving sorafenib (HR ¼ 0.665;
95% CI, 0.544-0.812, P o 0.0001).9 Similarly, a
statistically signiﬁcant PFS beneﬁt was also found in
favor of axitinib over sorafenib in the subgroup of
patients previously treated with only sunitinib, with a
median PFS of 4.8 months for axitinib and 3.4 monthsNovember 2015for sorafenib (HR ¼ 0.741; 95% CI, 0.573-0.958, P ¼
0.0107).9
Overall, both everolimus and axitinib therapies appear
to provide PFS beneﬁt for patients with advanced RCC
who previously progressed with sunitinib treatment;
however, because the overall study populations for the
RECORD-1 and AXIS trials are not directly comparable
due to population heterogeneity, a naive comparison of
the trial results cannot be used to draw conclusions
regarding relative efﬁcacy in this context. This study aims
to address this gap by performing a weight-adjusted
indirect comparison to balance clinical and demographic
characteristics between the 2 pivotal Phase III trial
populations. Similar weighting methods have previously
been used to balance patient characteristics among differ-
ent studies when patient-level data are available for one
treatment and only summary-level data for the compara-
tor treatment.10,11 Although performing a randomized
clinical trial is preferable, such studies can provide
valuable insight until direct evidence becomes available.
METHODS
Data from the RECORD-16 and the AXIS12 Phase III
clinical trials were used to perform a weight-adjusted
indirect comparison to align population characteristics
and compare PFS for everolimus versus axitinib. Both
clinical trials were multicenter, double-blind randomized
clinical trials that evaluated PFS as their primary end
point. Individual patient data were available from the
RECORD-1 trial for everolimus patient follow-up,
whereas only summary data were available for analytical
purposes in this analysis for axitinib-treated patients. PFS
estimates for the prior-sunitinib subgroup of the AXIS
clinical trial (N ¼ 194) were obtained from the AXIS
publication,9 whereas aggregated patient characteristics
for those receiving axitinib were retrieved from data
reported in a summary of the Evidence Review Group
report on the manufacturer’s National Institute for
Health Care Excellence submission.12 Survival data
were extracted by digitizing the available Kaplan-Meier
curve using the open source Engauge Digitizer software,
version 4.1 (Engauge, Atlanta, Georgia). The overall
everolimus population in the RECORD-1 trial
(N ¼ 277) consisted of patients with potentially multiple
prior lines of therapy. A subset (n ¼ 43) of patients with
second-line mRCC receiving everolimus who were suni-
tinib refractory was identiﬁed in RECORD-1 to corre-
spond with patients with second-line sunitinib-refractory
mRCC receiving axitinib from the AXIS trial (n ¼ 194).2553
Clinical TherapeuticsAfter limiting the RECORD-1 population to pa-
tients with second-line sunitinib-refractory mRCC,
heterogeneity in the patient characteristics between
the axitinib- and everolimus-treated patient groups
persisted (Table I). Further adjustments were
necessary to improve the comparability between the 2
studies; however, because patient characteristics and
outcomes for patients receiving axitinib were reportedTable I. Characteristics before and after matching of
second-line everolimus.*
Characteristic
RECORD-
Prematched sunitinib-refractory
second-line everolimus
group (n ¼ 43)
Post
Age, mean (IQR) 58 (32–79)
Sex
Male 70
Female 30
Ethnic origin
White 95
Black –
Asian 2
Other 2
ECOG performance status score†
0 42
1 58
41 0
MSKCC risk subgroups‡
Favorable 19
Intermediate 58
Poor 23
NA 0
Prior nephrectomy 88
Prior radiation 33
Time receiving prior sunitinib, mo
o9 79
Z9 21
AXIS ¼ axitinib versus sorafenib; ECOG ¼ Eastern Cooperativ
Memorial Sloan-Kettering Cancer Center; NA ¼ not applicab
Treatment With Oral RAD001 Given Daily.
*Data are presented as percentage of patients unless otherwise
†RECORD-1 distribution based on Karnofsky Performance Statu
‡Prognostic variables used in the weighting algorithm.
2554only as summary measures, any attempt to align
population characteristics between the everolimus and
axitinib treatment arms was limited to adjustments to
the RECORD-1 data.
In the data exploration, a bimodal distribution of
survival times was observed, mixing predominantly
2 groups of responders (ie, slow vs fast progressors).
As a consequence, a mixture of the 2 Weibullpatients with sunitinib-refractory disease receiving
1
AXIS sunitinib-
refractory axitinib
group (n ¼ 194)
matched sunitinib-refractory
second-line everolimus
group (n ¼ 43)
58 (32–79) 61 (20–82)
65 74
35 26
96 NR
0 NR
2 NR
2 NR
48 52
52 48
0 0
26 20
44 41
30 36
0 3
93 88
23 23
48 50
52 50
e Oncology Group; IQR ¼ interquartile range; MSKCC ¼
le; NR ¼ not reported; RECORD-1 ¼ Renal Cell Cancer
indicated.
s score o80 as ECOG performance status score of 1.
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lations was evaluated. This approach allowed for the
estimation of a latent classifying parameter for each
patient together with their probability to be fast or
slow progressor.
To account for the bimodal nature of the survival
distribution using patient data for the true second-
line sunitinib-refractory RECORD-1 population
(N ¼ 43), a latent class mixture model was used
with imbedded logit regression to reﬂect the mixture
of responders and nonresponders. Latent class mix-
ture models are useful for modeling heterogeneous
longitudinal data by assigning patients into
subgroupings.13
Conditionally to responder status, PFS was mod-
eled as a Weibull regression with prognostic variables
included as factors in a linear regression of the
logarithm of the parameter scale deﬁning the Weibull
function. The following candidate covariates were
considered: age, sex, Eastern Cooperative Oncology
Group (ECOG) performance status, Memorial Sloan-
Kettering Cancer Center (MSKCC) risk score, prior
nephrectomy, prior radiation therapy, and time
receiving prior sunitinib. The covariates included in
the logistic regression to deﬁne responder status were
those from the list above that had statistical signiﬁ-
cance (P o 0.05) in the Weibull model without
considering the latent class variable, namely, sex and
prior nephrectomy.
The mixture latent class model was then ﬁtted in a
Bayesian set-up with noninformative uniform priors.
On the basis of a posterior distribution on parameters
495%, MSKCC risk score, sex, time receiving prior
sunitinib, and prior nephrectomy were identiﬁed as
inﬂuential variables for PFS outcomes. These variables
were evaluated for independence using χ2 tests of
independence comparing all factors with each other.
Through these exercises, MSKCC risk score, sex, and
time receiving prior sunitinib were identiﬁed as key
characteristics to weigh to balance the RECORD-1
patient data to match the summary characteristics
reported in the AXIS publications. Prior nephrectomy
was not considered as a weighting characteristic
because of observed colinearity with the time receiving
prior sunitinib variable.
Weights were calculated for each patient by divid-
ing the proportion (Pi) of patients observed in AXIS
for a given key characteristic by the proportion
observed in RECORD-1 and multiplying theseNovember 2015quotients for all 3 weighting variables considered,
according to the following equation:
Wi¼ Pi AAXISð Þ=Pi ARECORD1ð Þ
 
 Pi BAXISð Þ=Pi BRECORD1ð Þ
 
 Pi CAXISð Þ=Pi CRECORD1ð Þ
 
where A indicates sex; B, MSKCC risk; and C, time
receiving prior sunitinib. The weight option in the
standard phreg procedure using SAS statistical soft-
ware, version 9.3 (SAS Institute Inc, Cary, North
Carolina), was used to account for weighting and
derive a new survival distribution for the adjusted
everolimus population. This new weighted survival
curve was then used to determine median PFS meas-
ures for patients with second-line disease receiving
sunitinib and everolimus. This estimate was compared
with the median PFS observed for patients receiving
axitinib in the AXIS trial. The 95% CIs were deter-
mined through bootstrapping techniques using Mat-
lab, release 14 (Mathworks, Natwick, Massachusetts).
The latent class model was ﬁtted with WinBUGS
software, version 1.4.3 (MRC Biostatistics Unit, Cam-
bridge, and Imperial College School of Medicine,
London, England). All other aspects of this analysis
were performed using SAS statistical software,
version 9.3.
RESULTS
The distribution of derived study weights were right
skewed with a mean (SD) of 1.0 (0.74) and a median
(interquartile range) of 0.76 (0.5–1.1) (Figure 1). After
applying weights, the distributions of the 3 key
baseline characteristics were more closely aligned
between the 2 studies; however, some differences
remained (Table I). The RECORD-1 mean age re-
mained slightly lower for the everolimus population
compared with the axitinib population. Both the
everolimus and axitinib populations had 23% of
patients with a history of radiation therapy. A slightly
lower rate of poor-risk patients based on MSKCC
criteria was present in RECORD-1 (30%) versus
AXIS (36%), and a 9% lower proportion of males
was observed in the postweighting everolimus group
compared with the axitinib population. Distributions
of time receiving prior sunitinib therapy were almost
equivalent between the everolimus and axitinib
treatment arms.
A median PFS of 4.7 months (95% CI, 3.5–10.6
months) was estimated for the weighted everolimus2555
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Figure 1. Distribution of study weights.
Clinical Therapeuticspatient group compared with 4.8 months (95% CI,
4.5–6.4) reported in the AXIS trial (Figure 2).
Results of the indirect analysis suggest
overlapping PFS CIs between everolimus and
axitinib.Su
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Figure 2. Kaplan-Meier progression-free survival curves for
2556DISCUSSION
After identifying key drivers of PFS and adjusting for
differences between the AXIS and RECORD-1 clin-
ical trials, the results of the weighted-adjusted
indirect comparison suggest similar PFS betweenAxitinib      4.8 (95% Cl, 4.5−6.4)
Everolimus 4.7 (95% Cl, 3.5−10.6)
e (mo)
10 11 12 13 14 15 16 17 18 19 20
patients in the axitinib and weighted everolimus groups.
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with RCC treated previously with sunitinib. This
analysis provides a more robust estimation of the
relative efﬁcacy between everolimus and axitinib
compared with a naive comparison that ignores
differences in trial inclusion criteria and distribu-
tions of prognostic variables. These ﬁndings are
consistent with those reported in a recently pub-
lished study.14
The indirect comparison analysis has several
limitations. Randomized clinical trials remain the
gold standard for clinical research, and as such,
these results are only intended to approximate a
clinical trial evaluating these 2 agents and should
only be interpreted as those from an observational
study. As with any observational study, bias may
result from observed and unobserved confounding.
The MSKCC risk score was deﬁned differently in the
RECORD-1 and AXIS trials. Although both trials
used high corrected calcium levels and low hemo-
globin levels as risk factors contributing to the
overall risk score, the RECORD-1 study used a
Karnofsky Performance Status (KPS) of o80 as
an additional risk factor, whereas the AXIS trial
considered ECOG performance status (PS) 40
(Table II). Levels of KPS do not directly
correspond with levels of ECOG PS, and as such, itTable II. Differences in MSKCC risk score
calculation between the RECORD-1
and AXIS clinical trials.
Risk Factors for the
MSKCC Score used in
RECORD-1*
Risk Factors in the
MSKCC Score used
in AXIS*
Corrected calcium Corrected calcium
Hemoglobin Hemoglobin
KPS score o80 ECOG performance
status score 40
AXIS ¼ axitinib versus sorafenib; ECOG ¼ Eastern
Cooperative Oncology Group; KPS ¼ Karnofsky
Performance Status; MSKCC ¼ Memorial Sloan-
Kettering Cancer Center; RECORD-1 ¼ Renal Cell
Cancer Treatment With Oral RAD001 Given Daily.
*A patient’s risk score was computed as the number of
risk factors.
November 2015is not possible to convert between KPS to ECOG PS
and maintain the same information (ie, an ECOG PS
of 0 requires no symptoms and no restrictions,
whereas a KPS of 80 requires symptoms and effort)
(Figure 3). This difference in how MSKCC risk
factors were determined likely led to inﬂated
MSKCC risk levels in the AXIS study population,
which may lead to an overestimation of PFS relative
to everolimus. Furthermore, the limited number of
second-line sunitinib-refractory patients in RECORD-1
(N ¼ 43) likely limited the precision of the derived PFS
estimate for the matched everolimus treatment group,
leading to a wide a CI of the estimate. The small sample
size in the everolimus analysis population may also have
adversely affected the ability to obtain exact distribu-
tional matches after weighting.
This analysis used a naive estimator to evaluate the
probability of a patient being in a group given certain
characteristics, which is highly dependent on sample
size to perform well.15 Weighting variables were
therefore limited to only those found to be
prognostic for PFS so as not to compromise the
functionality of this estimator. In doing so,
prognostic variables identiﬁed by statistical modeling
of RECORD-1 data were assumed to also be prog-
nostic in the AXIS trial population. Although sex,
MSKCC risk, and time receiving prior sunitinib were
identiﬁed through this process, sample size limitations
may have limited the ability to detect an association
between other variables and PFS. In addition, the
multivariate modeling revealed an association between
PFS and time receiving prior sunitinib therapy; how-
ever, this result is not consistent with real-world
ﬁndings where no association was found.16,17 This
could be explained by the very different contexts in
which the studies were performed (ie, it is possible
that the results observed in this study may only hold
true in the controlled environment of a randomized
clinical trial).
This approach also required the assumption that
residual differences in nonprognostic variables were
negligible. This may not always be the case. For
example, a higher proportion of Asians in the
overall AXIS trial population versus RECORD-1
may have led to bias in the PFS result in favor of
axitinib over everolimus because subanalyses in
the AXIS trial suggest a stronger PFS treatment
effect in nonwhites (HR = 0.524; 95% CI, 0.338–
0.812) compared with whites (HR = 0.733; 95%2557
KPS
Score
100 0
190
80
70
Normal; no complaints; no evidence of
disease
Asymptomatic (Fully active, able to carry on
all predisease activities without restriction)
Symptomatic but completely ambulatory
(Restricted in physically strenuous activity
but ambulatory and able to carry out work
of a light or sedentary nature. For example,
light housework, office work)
Cares for self; unable to carry on normal
activity or do active work
Able to carry on normal activity; minor
signs or symptoms of disease
Normal activity with effort; some sign or
symptoms of disease
Description
ECOG
Score Description
Figure 3. Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG)
performance status scores used to calculate Memorial Sloan-Kettering Cancer Center risk
scores.
Clinical TherapeuticsCI, 0.587–0.916). Additional head-to-head studies
evaluating everolimus versus axitinib should be
performed to conﬁrm these results.CONCLUSIONS
Similar median PFS point estimates (4.7 vs 4.8
months) with overlapping CIs suggest that ever-
olimus and axitinib have similar efﬁcacy. Although
the study ﬁndings should not be considered conclu-
sive without conﬁrmatory direct head-to-head evi-
dence, indirect comparison studies can be used to
support clinical and reimbursement decisions, par-
ticularly in an ever-changing treatment landscape.18
In this context, because the study results suggest
similar efﬁcacy in the population analyzed,
reimbursement decisions may focus on overall cost
of therapy and the potential effect of the safety
proﬁle. Because new data on these products are
generated for the population with second-line suni-
tinib-refractory disease receiving everolimus, this
analysis may be reproduced with a larger study
population and more statistical power. Such studies
may be used to further support any future reim-
bursement decisions and to elucidate the most
appropriate and cost-effective sequence of therapy
in this setting.2558ACKNOWLEDGMENTS
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